Phase III Randomised Clinical Trial for Stage III Ovarian Carcinoma Randomising Between Secondary Debulking Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy

Trial ID # NCT00426257; OVHIPEC-1
Phase III
Drug Class Chemotherapy
Drug Name HIPEC
Alternate Drug Names Hyperthermic Intraperitoneal Chemotherapy
Drugs in Trial Carboplatin, HIPEC, Paclitaxel
Eligible Participant

Stage III epithelial ovarian cancer with CR, PR or SD after 3 cycles of neoadjuvant carboplatin+paclitaxel

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Randomized


RFS, OS, evaluated per RECIST or CA125


CarboPt+Pac+HIPEC vs CarboPt+Pac+Placebo:

RFS: 14.3 vs 10.7 months, HR: 0.63 (0.48-0.83, p=0.0008)
OS: 44.9 vs 33.3 months, HR: 0.70 (0.53-0.92, p=0.011)

Exploratory analysis, BRCA/HRD status:
BRCA MUT: RFS: HR: 1.25 (0.48-3.29)
BRCA WT/HRD+: RFS: HR: 0.44 (0.21-0.91)
BRCA WT/HRD-: RFS: HR: 0.82 (0.48-1.42)

Clinically Significant Adverse Events

CarboPt+Pac+HIPEC vs CarboPt+Pac+Placebo:
Serious AE:
Grade 3-4 AE: overall (27 vs 25%)


Among patients with stage III ovarian cancer, the addition of HIPEC to interval cytoreductive surgery resulted in longer RFS and OS than surgery alone and did not show higher rates of side effects


van Driel WJ et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med (2018) 18;378(3):230-240

Koole SN et al. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial. Int J Cancer (2022) 151(8):1394-1404

Lot Aronson S et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol (2023) 24(10):1109-1118

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.